JPMorgan raises Santen Pharmaceutical price target on medium-term plan

JPMorgan raised its price target on Santen Pharmaceutical (SNPHY) to JPY2,600 from JPY2,200, maintaining an Overweight rating, after the company's Q4 fiscal 2024 results and new medium-term plan. Santen's plan targets fiscal 2029 sales of JPY400 billion and core operating profit of JPY80 billion, with Ryjusea sales exceeding JPY1.6 billion in fiscal 2025 seen as a key milestone. A share buyback program of up to JPY35 billion is also expected to support the stock price.

Analysis

JPMorgan has upgraded its outlook on Santen Pharmaceutical Co., Ltd., increasing its price target to JPY2,600.00 from JPY2,200.00 and reiterating an Overweight rating. This revision is predicated on Santen's fourth-quarter fiscal 2024 performance and, more significantly, its newly unveiled medium-term plan spanning fiscal years 2025-2029. The plan sets ambitious targets, aiming for JPY400 billion in sales and JPY80 billion in core operating profit by fiscal 2029, figures which JPMorgan acknowledges are viewed as challenging by many in the investment community. A critical early indicator for the success of this long-term strategy will be the fiscal 2025 performance of Ryjusea, Santen's treatment for myopia progression; achieving sales exceeding the JPY1.6 billion guidance for this drug is seen as a key milestone that could bolster investor confidence. Furthermore, Santen's share buyback program, valued at up to JPY35 billion and active from May 22 to November 5, is anticipated to provide near-term support to the stock price.

Key Decisions for Investors

• Investors should note JPMorgan's Overweight rating and increased price target for Santen Pharmaceutical, viewing it as a positive signal, while remaining cognizant of the ambitious nature of the company's fiscal 2029 financial targets.
• Closely monitor Ryjusea's sales figures in fiscal 2025, as performance exceeding the JPY1.6 billion guidance could significantly de-risk the medium-term plan and positively impact Santen's valuation.
• Consider the ongoing JPY35 billion share buyback program, scheduled to conclude on November 5, as a potential source of near-term price stability and a factor supporting the stock during this period.